Related Experiment Video
Updated: Sep 2, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Need for revision: EC process, members' training, and compensation formula in the New Drugs and Clinical Trials Rules
1Scientia Clinical Services, Pune, Maharashtra, India.
Abstract:
The New Drugs and Clinical Trial Rules (NDCTR) came in force in 2019, these brought in some changes, but certain earlier parts, such as Rule 122 DAB, were incorporated unchanged. A few sections of the NDCTR are problematic and need revision for the smooth conduct of clinical trials in India. Training of Ethics Committee (EC) members and other stakeholders is a very important driver for clinical research but has not been defined clearly. In addition, some processes of EC review need a relook. Compensation formulae were finalized in 2013; now, the altered economic situation has eroded the value of money. Hence, for the protection of research participants, an urgent review of the compensation formula is suggested.
More Related Videos
Related Concept Videos
Clinical Trials: Overview
Drug Regulation
Clinical Trials
There are four phases in a clinical trial. A phase one...
Preclinical Development: Overview
Drug Control Governance: Regulatory Bodies and Their Impact
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

